Results 181 to 190 of about 64,876 (258)

Multimodal prognostic models for bladder urothelial carcinoma: uroplakin III combined with serum and demographic data. [PDF]

Front Oncol
Feng R, Hou J, Tao Y, Wang Y, Li S, Dong X, Tai W.   +6 more
europepmc   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and Metastasis in Bladder Urothelial Carcinoma. [PDF]

Hum Mutat
Sun Y, Yi X, Zhou C, Huang Y.
europepmc   +1 more source

Bladder urothelial carcinoma

, 2013
openaire   +1 more source

Clinical Benefit of PD‐1/PD‐L1 Inhibitors as Standard First‐Line Treatment in Low PD‐L1‐Expressing Advanced Solid Tumors: A Systematic Review and Meta‐Analysis

MedComm, Volume 7, Issue 2, February 2026.
This is the first meta‐analysis to focus on the actual clinical benefit of ICIs as standard first‐line therapy for multiple cancers with low PD‐L1 expression, in accordance with current FDA guidelines. The mirror‐based study design enhances precision and accuracy, while ensuring alignment with clinical practice.
Peng Wu, Xuanyu Gu, Dongyu Li, Xiaohui Zi, Dexin Shang, Jingjing Liu, Ruijie Ma, Jilin Peng, Guochao Zhang, Yun Che, Qingpeng Zeng, Bohui Zhao, Nan Sun, Chaoqi Zhang, Jie He   +14 more
wiley   +1 more source

Review of recent molecular pathology of bladder urothelial carcinoma. [PDF]

Discov Oncol
Su P, Yang Y, Zheng H.
europepmc   +1 more source

Exploring Pembrolizumab‐Induced IM3OS in a Patient With Bladder Cancer

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT Pembrolizumab, an immune checkpoint inhibitor (ICI), has transformed cancer treatment across various malignancies, including metastatic urothelial cancer. As the use of pembrolizumab becomes increasingly widespread, understanding its potential adverse effects is essential.
Ching‐Cheng Chan, Ming‐Jen Lee, Jian Su, Jen‐Jen Su   +3 more
wiley   +1 more source

Predicting early death in elderly patients with bladder urothelial carcinoma: a population-based study. [PDF]

Transl Androl Urol
Huang Q, Hu Q, Jiang M, Wang B, Che X.
europepmc   +1 more source

Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer

BJU International, Volume 137, Issue 2, Page 339-347, February 2026.
Objective To report long‐term oncological outcomes of patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) undergoing bladder‐sparing therapy (BST) after bacillus Calmette–Guérin (BCG) failure. Patients and Methods We retrospectively reviewed patients with HR‐NMIBC treated from 2000 to 2025 with intravesical therapies after BCG failure,
Ian M. McElree, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Vignesh T. Packiam, Michael A. O'Donnell   +5 more
wiley   +1 more source

Correction: MED10 drives the oncogenicity and refractory phenotype of bladder urothelial carcinoma through the upregulation of hsa-miR-590. [PDF]

Front Oncol
Wu CC, Wang YH, Hu SW, Wu WL, Yeh CT, Bamodu OA.   +5 more
europepmc   +1 more source